For best experience please turn on javascript and use a modern browser!
Bekijk de site in het Nederlands

When a woman with blood group D- is pregnant with a child with blood group D+, the mother’s immune system can be activated, resulting in the production of antibodies. These antibodies can enter the child’s bloodstream before or during birth, attacking their red blood cells. This condition is called hemolytic disease of the fetus and newborn and children affected are known as Rhesus babies. To prevent these adverse effects, pregnant women with D- are now given an antenatal injection of Rh prophylaxis, also known as anti-D. It is produced from the plasma of hyperimmunized anti-D donors and is therefore in limited supply. Tamara Stegmann’s research focuses on experimental models for studying the working mechanisms of anti-D, so effective recombinant antibodies can be developed that can be used as an alternative source.

Event details of Studying antibody mechanisms to prevent hemolytic disease in babies
Date 29 September 2016
Time 14:00 -15:00
Location Agnietenkapel
Room Location

T.C. Stegmann: Immune Response to Red Blood Cell Antigens.

Supervisor

Prof. C.E. van der Schoot

Co-supervisor

Dr G. Vidarsson (Sanquin Research)

Agnietenkapel

Room Location

Oudezijds Voorburgwal 229 - 231
1012 EZ Amsterdam

Entrance

This event is open to the public.